Portola pharmaceuticals, inc. (PTLA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-68,771

-96,676

-49,627

-68,477

-78,096

-88,886

-71,177

-105,971

-84,510

-91,501

-82,941

-69,414

-41,764

-54,764

-91,036

-57,339

-64,974

-66,106

-55,157

-58,329

-46,913

-39,256

-35,793

-31,350

-30,726

-25,062

-18,549

-21,599

-18,142

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

638

663

780

765

792

799

777

770

756

743

665

498

504

501

497

469

457

369

313

240

389

400

400

384

358

344

336

343

336

Operating Lease, Cost

1,171

1,168

975

622

459

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on investment securities

139

279

312

372

262

345

475

553

491

452

33

-89

-161

-151

-1,721

285

474

-5,722

745

871

932

1,034

821

904

944

810

705

373

445

Non-cash interest expense

5,066

4,155

6,197

8,538

6,481

6,098

5,957

4,104

2,581

3,359

3,149

3,456

1,639

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense, net of capitalized labor

9,480

10,882

11,046

12,253

17,894

19,773

11,393

13,214

10,980

10,879

10,114

13,257

9,034

7,898

7,773

7,622

7,069

6,826

6,101

4,759

5,172

2,457

2,150

2,424

2,302

1,517

1,534

1,210

713

Embedded Derivative, Gain (Loss) on Embedded Derivative, Net

-3,169

-516

545

2,430

472

2,689

2,099

-65

1,634

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for excess and obsolete inventories

2,110

21

311

-125

3,945

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency remeasurement loss

-252

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revaluation of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

11

-35

Unrealized loss on foreign currency forward contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18

17

-

-

182

-534

Changes in operating assets and liabilities:
Inventories

15,601

61,142

552

-1,366

-1,498

-2,985

9,614

3,834

2,149

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade and other receivables, net

-6,137

-4,689

4,281

2,168

5,938

-1,301

3,729

1,728

-4,763

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unbilled - collaboration and license revenue

-375

-5

-1,007

-1,522

-3,563

8

3,381

1,831

-2,034

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

-12

-45

-16

-109

18

-145

82

-3,267

2,536

296

Prepaid research and development

-

-

-

-

-

-

-

-

-

-

-1,599

-2,411

-1,401

-

-6,903

11,624

-6,122

-2,463

6,568

4,109

7,076

-

-

-

-

-

-

-

-

Prepaid and other current assets

2,328

-2,156

648

-318

-1,986

4,243

-15,679

7,688

11,244

-6,322

2,604

2,851

632

-11,592

-667

1,968

236

1,999

-2,035

-167

-798

586

-479

-142

1,418

-

-

-

-

Prepaid and other long-term assets

-3,230

5,449

1,261

-13,939

11,042

16,443

4,120

-4,798

-4,797

0

3,332

2,109

-1,046

-1,102

-9,702

4,841

-816

-994

-923

-768

-934

5,605

10,001

-28

-19

-

-

1,508

-417

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,200

971

Accounts payable

585

315

340

1,182

-4,489

-2,868

7,742

-14,462

11,469

-8,668

6,191

2,358

-5,123

5,594

4,157

-8,787

3,344

1,271

-3,991

7,486

-8,827

1,409

6,653

-1,414

4,115

1,550

-3,159

-2,232

2,068

Accrued compensation and employee benefits

-

-

-

-

-

-

-

-

-

-

3,350

2,161

-1,407

1,289

-1,118

1,926

-2,750

1,671

921

1,216

-1,754

933

281

561

-882

647

190

604

-791

Accrued research and development

-2,019

3,620

-2,770

23

-1,455

3,156

-22,340

16,910

-22,868

20,829

2,094

10,881

-12,649

8,385

-5,074

2,933

-6,621

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

-10,243

14,554

-1,719

1,608

3,225

1,799

2,325

3,714

-4,324

6,495

739

-245

1,587

-643

-1,026

640

137

-745

1,468

-9,612

10,420

349

-2,131

4,327

-2,806

-10,838

1,851

6,274

1,879

Deferred revenue

-491

515

-222

-956

303

-1,108

-2,679

849

1,650

-3,053

-3,828

-3,787

-5,128

2,058

-5,322

4,019

17,992

-2,415

-2,410

-2,386

-2,358

-2,413

15,573

4,086

14,128

-2,056

234

1,099

1,892

Notes payable and long term royalty-based debt

-3,721

-

-

-

-2,027

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-245

-244

-246

-230

-208

-225

-227

-205

-204

-194

-205

-166

759

-11

440

1,093

-460

-96

-87

601

-223

-222

-224

-209

Net cash used in operating activities

-71,100

-73,338

-46,885

-54,065

-63,635

-63,381

-82,368

-91,889

-88,420

-65,712

-58,880

-48,997

-51,536

-13,381

-77,868

-66,870

-38,336

-57,185

-54,152

-48,770

-47,145

-44,059

-23,415

-19,995

-13,237

-20,709

-13,579

-17,167

-12,160

Investing activities
Capital expenditures, net

963

459

294

464

327

982

314

751

512

-306

1,238

191

113

300

-239

468

1,335

1,596

595

1,492

1,063

300

366

568

395

351

249

40

293

Decrease (increase) in restricted cash (SRX Cardio)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,785

-117

-79

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

46,473

154,213

137,756

35,070

41,708

40,753

51,386

88,896

78,048

201,648

187,569

38,626

147,781

54,673

42,214

102,892

52,544

78,902

19,514

76,712

90,940

176,162

12,516

66,938

76,555

67,020

54,153

86,773

11,867

Proceeds from sales of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,000

1,365

2,000

2,144

2,500

Proceeds from maturities of investments

100,363

76,058

54,073

43,020

124,138

97,403

101,545

88,634

148,141

102,795

79,764

75,225

95,304

100,111

80,241

98,694

115,684

82,678

79,323

60,660

101,439

46,384

34,645

79,871

31,145

23,790

14,275

27,927

26,009

Net cash provided by investing activities

52,927

-78,614

-83,977

7,486

82,103

55,668

49,845

-1,013

69,581

-98,547

-109,043

31,408

-52,590

46,727

36,481

-4,549

61,884

1,828

59,214

-17,533

9,436

-127,475

18,763

12,365

-42,805

-42,216

-38,127

-56,742

16,349

Proceeds from debt issuance, net

0

62,500

0

0

59,203

-

-

-

-

-556

0

0

48,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

269

89

164

Debt issuance costs paid

-

-

-

-

-

-

-

-

-

-

0

21

536

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock pursuant to equity award plans

379

1,814

6,479

5,966

10,637

754

6,413

2,544

5,678

2,079

7,940

5,776

3,847

-232

701

62

910

1,204

3,749

2,726

4,269

1,044

967

1,697

1,270

-

-

-

-

Payments of long-term obligation to collaborator

278

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

0

0

-21

-119

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from public offering of common stock, net of underwriters discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

108,772

-

-

-

-

-

-

-

-

Payment of public offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

242

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

101

63,214

250,544

5,966

69,840

754

6,413

97,523

5,559

1,809

388,105

5,755

51,311

56,310

701

62

668

164,124

3,749

2,368

113,041

175,904

728

1,697

1,270

121,988

-1,830

128,189

164

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-23

-78

119

-43

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-18,095

-88,816

119,801

-40,656

88,308

-6,959

-26,110

4,621

-13,280

-162,450

220,182

-11,834

-52,815

89,656

-40,686

-71,357

24,216

108,766

8,811

-63,935

75,332

4,370

-3,924

-5,933

-54,772

59,063

-53,536

54,280

4,353